Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial.
Petros D GrivasElena GarraldaFunda Meric-BernstamIngo K MellinghoffLipika GoyalJames J HardingElizabeth C DeesRastislav BahledaNilofer S AzadAsha KarippotRazelle KurzrockJosep TaberneroJuha KononenMatthew Chau Hsien NgRutika MehtaNataliya V UbohaFrédéric BigotValentina BoniSamantha E BowyerValeriy BrederAndres CervantesNancy ChanJames M ClearyMallika DhawanRikke Helene Løvendahl EefsenJames EwingDonna M GrahamTormod Kyrre GurenJin Won KimKrassimir KoynovDo Youn OhRebecca A RedmanChia-Jui YenDavid B SpetzlerMarie-Claude Roubaudi-FraschiniValérie NicolasRafik Ait-SarkouhClaudio ZannaAbdallah EnnajiAnna Pokorska-BocciKeith T FlahertyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Debio 1347 had manageable toxicity; however, the efficacy in patients with tumors harboring FGFR fusions did not support further clinical evaluation in this setting. Our transcriptomic-based analysis characterized in detail the incidence and nature of FGFR fusions across solid tumors.